Covex has been manufacturing GMP-certified, high-quality Active Pharmaceutical Ingredients (Vinpoceitne, Vincamine and Vinburnine) for pharmaceutical industries around the world since 1977.
The level of expertise obtained over these years by our highly-qualified staff ensures a solid guarantee of complying not only with the highest standards set by Health Authorities, but of satisfying the most important standard of all – our customers’ satisfaction.
Our ingredients are derived from Voacanga Africana and are processed by high-technology equipment assessed regularly and compliant with ICH norms.
Covex S.A.’s manufacturing site has been increasing in terms of capacity and production volumes over the years, whilst giving maximum priority to ensuring that the excellent quality of its goods is maintained. In addition to the GMP Certificate approved for the manufacture of APIs, the laboratory is also GMP certified, with the EU Authorisation for Drug Manufacturers and Importers, duly certified by the AEMPS (Spanish Medicines and Health Products Agency). The modern factory design has a custom-made area for receiving and preparing raw materials, 2 extraction lines, 5 synthesis reactors and a drying and grinding system (Grade “D” or ISO 8).
All facilities at Covex comply strictly with current environmental, health and safety legislation.
One of the paramount objectives as a factory is to guarantee the high-quality standard of our final products in order to successfully compete on the international market and, more importantly, to satisfy our customers’ needs. For this reason, the goods manufactured by Covex comply with all current requirements established both within the European Union and beyond its frontiers.
The Standardization of the manufacturing process of pharmaceutical products is generally considered the principal quality assurance in terms of batch production, and it guarantees the effectiveness and safety of the use. Quality assurance is achieved by implementing Covex’s Quality Assurance System: a range of activities, technology, methods and tools handled by highly-trained experts to create and control the optimum quality standards throughout the entire manufacturing process.
Specifications relating to the quality of the goods obtained in Covex are designed to fulfil the principles, norms and requirements set out by the Pharmacopoeias worldwide, the ICH and the FDA.
The equipment used is assessed regularly, and the processes and methods of control are validated in accordance with ICH norms.
Compliance with the European GMP norms and the marketing authorisation for active ingredients is certified by the AEMPS (Spanish Medicines and Health Products Agency), thereby allowing the company to market its high-quality active ingredients internationally.
Covex has invested greatly in Research and Development, having worked closely with the Complutense University of Madrid.
Leader in the production of the periwinkle family products, Covex has developed a unique method of extraction in advanced chemistry meaning that, today, it can guarantee high quality production at optimum standards able to compete internationally.
Covex has a considerable patent and trademark portfolio, with intellectual property rights in more than 100 countries.
Covex at 1980
Covex at 00’s
Covex was founded in 1977 and began carrying out research on medicinal plants that normally have pharmacological activity, specifically the Voacanga Africana.
A significant moment was when Covex entered the Soviet Union in 1991, thanks to the patent that had been granted a few years earlier for that area of the world, when the company had only 20 employees.
This patent led to a contract with the USSR Health Department for a value of 9 million US Dollars, for selling Vinpocetine tablets (Vinpocetine Covex 5 mg), a medicine for neurological use.
In addition to the significant commercial success achieved then, that circumstance has made it possible that today we can still maintain the permanent presence acquired over the past few years in Russia and the ex-Republics, as one of Spain’s largest exporters of medicinal drugs.
Our commercial growth allows Covex to export to customers in five continents.
Our competitiveness in quality and price, together with an investment of 6 million Euros made, to expand the factory’s capacity, in addition to the boom of nutraceuticals market, has kept us in a leading position in this field since 1977.
Our intellectual property, advanced manufacturing technology, and constant research in this field ensure our production in the current pharmaceutical industry whilst introducing new products for functional foods.
We are reaching an increasing segment of the world market, and we hope to occupy the first place within the forthcoming years.
China Pioneer Pharma Holdings Ltd.
On 1 July 2014 China Pioneer Pharma Holdings Ltd acquired COVEX SA; since then, COVEX forms part of a Group listed on the Hong Kong Stock Exchange.
Pioneer Pharma is one of the largest comprehensive marketing, promotion and channel management service providers dedicated to imported pharmaceutical products and medical devices in China.
Founded in 1996, Pioneer has been growing fast. Today, it has established an impressive service network covering over 20,000 hospitals and other medical institutions across 31 provinces, municipalities and autonomous regions in China. Its business headquarters is located in Shanghai, the commercial center of China, and its logistics hub is situated in Hubei province, one of the best connected and centrally located areas in the country.
It is a young, dynamic company which embraces both traditional Chinese values and Western business culture and practices. Its business partners choose it because of its strong track record, impressive service network, diligent care for quality, and clear communications.